title: Recognition of biomarker identified high-risk patients in the acute medically ill venous thromboembolism prevention with extended duration betrixaban study resulting in a protocol amendment.
authors.affiliation: Guys and St Thomas' NHS Trust, Department of Haematology, London, United Kingdom. Electronic address: alexander.cohen@kcl.ac.uk.
authors.forename: Alexander T
authors.initials: AT
authors.lastname: Cohen
authors.affiliation: Stanford University School of Medicine, Interventional Cardiology, Stanford, CA.
authors.forename: Robert
authors.initials: R
authors.lastname: Harrington
authors.affiliation: Brigham and Women's Hospital, Cardiovascular Division, Boston, MA.
authors.forename: Samuel Z
authors.initials: SZ
authors.lastname: Goldhaber
authors.affiliation: University of Calgary, Thrombosis Research Unit, Calgary, Alberta, Canada.
authors.forename: Russell
authors.initials: R
authors.lastname: Hull
authors.affiliation: Beth Israel Deaconess Medical Center, Cardiovascular Division, Boston, MA.
authors.forename: C M
authors.initials: CM
authors.lastname: Gibson
authors.affiliation: Duke University, Duke Clinical Research Institute, Durham, NC.
authors.forename: Adrian F
authors.initials: AF
authors.lastname: Hernandez
authors.affiliation: Portola Pharmaceuticals, San Francisco, California, United States of America.
authors.forename: Alex
authors.initials: A
authors.lastname: Gold
mesh_terms: D000925:Anticoagulants / Q000008:administration & dosage*; D001549:Benzamides / Q000008:administration & dosage*; D017984:Enoxaparin / Q000008:administration & dosage*; D065427:Factor Xa Inhibitors; D006801:Humans; D011725:Pyridines / Q000008:administration & dosage*; D054556:Venous Thromboembolism / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants; D001549:Benzamides; D017984:Enoxaparin; D065427:Factor Xa Inhibitors; D011725:Pyridines